biOasis Technologies Ord Shs V.BTI.H

Looks like fuzzy is all in.

[JDavenport]

I think that because too many people think that I'm making this all about me, I have to step back.

I'm on the record. It's very likely that Bioasis and xB3 are going to disappear from your lives and I've told you how and why it can be accomplished with this deal. I warned about it four years ago and I was voted down. Other people gave Rathjen control of Bioasis. I fought against it. They can live with it. Unfortunately, you have to live with it, too.

Join fuzzy and vote for this if you must, but if it goes south on you, don't ever make the mistake of telling me I was right. 

I have become friends with so many of you. I'm sad that this is failing for you. I'm very upset that I was pretty much killed off by it. Rathjen is winning and you are going to have a very tough time accepting that down the road. I wish I could have been of more help to myself and you. 

Ok, I'm off to make a living. I'll be close by. If I think I have anything to say that is helpful, I'll post it.

jd

[prophetoffactz]

"I think that because too many people think that I'm making this all about me, I have to step back."  Are you sure that you are not making it about you instead of Biodexa, jd? You say xB3 is being downplayed in the deal when if you look at Midatech's news release about the deal xB3 is very important. The news release explicitly states BTI is developing xB3 and states it has

[JDavenport]

Yes, pof, Midatech has listed the potential value of existing Bioasis deals. Biodexa gets those deals, and can therefore say they can benefit from xB3. They also claim that xB3 can help the Midatech legacy programs. They get Hunter sysndrome, the disease for which Denali and JCR are way ahead. I won't say its worthless but will it be worth advancing with Biodexa so short of money and with

[prophetoffactz]

You may be able to add importantly to this list jd? With Biodexa Is xB3 potentially in the strongest hands it has ever been in to get out of this decade long quagmire that it has been in? The new merged company, Biodexa: 1) Still has control of xB3.  2) Has clinical trial infrastructure to advance clinical trials itself and enter into more significant strategic alliances. 3) Has US NASDAQ

[JDavenport]

Hah! Biodexa will have control of xB3, but they've placed value only on existing xB3 deals, and on xB3 helping the Midatech legacy programs. Otherwise, none of the players in this deal have expressed anything about the value of the xB3 platform. I've explained why I think that is so. Meanwhile, Bioasis and Midatech are burning to the ground and the deal gang are doing nothing to prevent

[MineDigger]

Is it agreed that control will be exercised by one share holder? If so it is never a good place to be for all the other shareholders, not to mention how diluted they are anyway. And as for the "totalling in excess of US$200 million plus royalties on net sales", don't forget to subtract whatever is due to Xoma, eg all the Prothena royalties (and 10% of the milestones and 100% of the

[JDavenport]

Yes, MineDigger, it's the poor disclosure and lack of disclosure, the hiding of events, situations and conditions that combine to make this deal worrisome. People will tell you how they operate, and will operate, if you watch them closely enough.  jd

[JDavenport]

About XOMA, I believe they have an option on the next Bioasis deal. I imagine that Biodexa must honour that option. It will be interesting to see what programs that XOMA can choose from after this deal is done. I would think that the XOMA agreement would anticipate this type of deal. It's XOMA's business model, after all. jd